SPECT imaging ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	14

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01931488 (ClinicalTrials.gov)	August 2013	14/8/2013	124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.	The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. Comparison With 123I-MIBG.	Parkinson Disease;Neuroendocrine Tumors	Other: MIBG label with I123 or I124;Device: SPECT imaging	Tel-Aviv Sourasky Medical Center	NULL	Recruiting	18 Years	N/A	Both	40	Phase 2	Israel
2	NCT00556764 (ClinicalTrials.gov)	July 2007	8/11/2007	Development of Cognitive Assessment Tools in Parkinson Disease	Development of Cognitive Assessment Tools in Parkinson Disease	Parkinson Disease	Drug: [123I] IBVM and SPECT imaging;Drug: Subjects will undergo the 123-I IBVM imaging visit	Institute for Neurodegenerative Disorders	Department of Defense;University of Oklahoma	Completed	30 Years	N/A	Both	75	Phase 0	United States
3	NCT00480701 (ClinicalTrials.gov)	February 2007	30/5/2007	Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease	Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer Disease	Alzheimer Disease;Parkinson Disease	Drug: [123I]-IBVM	Institute for Neurodegenerative Disorders	NULL	Completed	50 Years	N/A	Both	26	Phase 2	United States
4	NCT00427674 (ClinicalTrials.gov)	January 2007	25/1/2007	Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients	Phase I Evaluation of (123-I)MZINT as a Brain SPECT Tracer of Serotonin Transporters in Healthy Human Subjects	Parkinson Disease	Drug: [123I] mZINT injection and serial dynamic SPECT imaging	Institute for Neurodegenerative Disorders	Molecular NeuroImaging	Terminated	18 Years	70 Years	Both	28	Phase 1	United States
5	NCT00397228 (ClinicalTrials.gov)	November 2006	6/11/2006	ALTROPANE® SPECT Imaging in Patients With Parkinson Disease	Optimizing the Performance of ALTROPANE® SPECT Imaging in Patients With Parkinson Disease	Parkinson Disease	Drug: ALTROPANE®	Molecular NeuroImaging	Institute for Neurodegenerative Disorders	Completed	30 Years	N/A	Both	27	Phase 2	United States
6	NCT00397696 (ClinicalTrials.gov)	November 2006	7/11/2006	Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease	Evaluation of 5-[123I]-A-85380 and SPECT Imaging as a Marker of Nicotinic Receptor Density in the Brain of Parkinson Disease Subjects	Parkinson Disease	Drug: [123I] 5-IA	Institute for Neurodegenerative Disorders	Department of Defense	Completed	21 Years	N/A	Both	9	Phase 2	United States
7	NCT00404170 (ClinicalTrials.gov)	November 2006	22/11/2006	Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease	Assessing the Determinants of PD Progression - Long-term Dopamine Transporter Imaging in the PRECEPT Cohort	Parkinson Disease	Drug: B-CIT and SPECT imaging	Institute for Neurodegenerative Disorders	United States Department of Defense	Completed	30 Years	N/A	All	396	Phase 2	United States
8	NCT00387075 (ClinicalTrials.gov)	November 2006	10/10/2006	A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease	Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease	Parkinson Disease	Procedure: [123I]ß-CIT and SPECT imaging;Drug: [123I]ß-CIT	Institute for Neurodegenerative Disorders	United States Department of Defense;Molecular NeuroImaging	Active, not recruiting	50 Years	N/A	All	3000	Phase 2	United States
9	NCT00129181 (ClinicalTrials.gov)	January 2005	9/8/2005	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease	A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease	Parkinson Disease;Parkinsonian Syndrome	Drug: cabergoline;Drug: carbidopa/levodopa;Procedure: DATscan and SPECT imaging	Institute for Neurodegenerative Disorders	Pfizer;GE Healthcare	Completed	40 Years	N/A	Both	30	N/A	Austria;Germany;Italy;Spain;United Kingdom
10	NCT00096720 (ClinicalTrials.gov)	February 2004	12/11/2004	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease	Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's	Parkinson Disease;Parkinsonian Syndrome	Drug: levodopa;Drug: Mirapex (pramipexole);Procedure: [123I]ß-CIT and SPECT imaging	Institute for Neurodegenerative Disorders	Boehringer Ingelheim;Department of Defense	Completed	30 Years	N/A	Both	112	Phase 2	United States
11	NCT00129675 (ClinicalTrials.gov)	February 2003	11/8/2005	Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty	Development of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's Symptoms	Parkinsonian Syndrome	Drug: [123I]ß CIT	Institute for Neurodegenerative Disorders	Molecular NeuroImaging	Completed	21 Years	N/A	Both	169	Phase 2	United States
12	NCT00117819 (ClinicalTrials.gov)	March 2001	30/6/2005	A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease	Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome	Parkinsonian Syndrome	Drug: [123I]ß CIT and SPECT imaging	Institute for Neurodegenerative Disorders	Indiana University;Albany Medical College	Completed	22 Years	N/A	Both	232	Phase 2	United States
13	NCT00134784 (ClinicalTrials.gov)	April 2000	23/8/2005	Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression	[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's Disease	Parkinson Disease	Drug: [123I]B-CIT SPECT imaging	Institute for Neurodegenerative Disorders	United States Department of Defense	Completed	22 Years	N/A	All	142	Phase 2	NULL
14	NCT00132626 (ClinicalTrials.gov)	September 1992	18/8/2005	Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome	Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism	Parkinson's Disease;Parkinsonian Syndrome	Drug: [123I]ß-CIT and SPECT imaging	Institute for Neurodegenerative Disorders	Molecular NeuroImaging;National Institutes of Health (NIH)	Completed	35 Years	N/A	All	500	Phase 2	NULL

Back to top